Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections
This product has only one approved generic and one authorized generic with an addressable market share of US$ 172 million
The partnership builds on a prior collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases
NTX-253 is a potent, selective, orally available positive allosteric modulator (PAM) of the muscarinic M4 receptor
Tiger Shroff fronts ‘Fit Raho, Hit Raho’ campaign
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
The trial aims to measure AF burden—the percentage of time patients spend in arrhythmia—as its primary efficacy endpoint
The MAGiC catheter is designed for robotically-navigated cardiac ablation procedures
Subscribe To Our Newsletter & Stay Updated
